Preliminary data from Phase 1 clinical trial using CAR-T-FAP injecting into the pleural cavity of malignant pleural mesothelioma patients have demonstrated the expansion of the antigen-targeting T cells (99, 134). The gene discussed is FAP; the disease is malignant pleural mesothelioma.